Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia

Human Psychopharmacology

Volumn , Issue , 2016, Pages 325-331

  Buoli, Massimiliano ^a,b   Kahn, René S ^b   Serati, Marta ^a   Altamura, A Carlo ^a   Cahn, Wiepke ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

haloperidol; maintenance treatment; schizophrenia; second generation antipsychotics

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; DIABETES MELLITUS; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RECURRENT DISEASE; SCHIZOPHRENIA; SIDE EFFECT; SURVIVAL ANALYSIS; WEIGHT GAIN;

EID: 84977639891     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2542     Document Type: Article

References (34)

1. Altamura AC, Buoli M, Mauri MC. 2011. Haloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia: a 4-year follow-up naturalistic study. J Clin Psychopharmacol 31: 661–3.
2. Altamura AC, Dragogna F. 2013. Should the term ‘antipsychotic’ be changed to ‘multidimensional stabiliser’ in bipolar disorder? Towards a new denomination for ‘atypical antipsychotics’. Aust N Z J Psychiatry 47: 707–9.
3. Altamura AC, Serati M, Buoli M. 2015. Is duration of illness really influencing outcome in major psychoses? Nord J Psychiatry 69: 403–17.
4. Andreasen NC, Carpenter WT, Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. 2005. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 162: 441–9.
5. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. 2010. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 67: 255–62.
6. Briggs A, Wild D, Lees M, et al. 2008. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 6: 105.
7. Ceskova E, Prikryl R, Libiger J, Svancara J, Jarkovsky J. 2015. Gender differences in the treatment of first-episode schizophrenia: results from the European First Episode Schizophrenia Trial. Schizophr Res 169: 303–7.
8. Crespo-Facorro B, Pérez-Iglesias R, Mata I, et al. 2011. Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison. J Psychopharmacol 25: 744–54.
9. Crespo-Facorro B, Pérez-Iglesias R, Mata I, et al. 2012. Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis. Psychopharmacology (Berl) 219: 225–33.
10. DeLisi LE, Fleischhacker WW. 2015. The problem of substance abuse in people with schizophrenia. Curr Opin Psychiatry 28: 199–200.
11. Dossenbach M, Pecenak J, Szulc A, et al. 2008. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. J Clin Psychiatry 69: 1901–1915.
12. First MB, Williams JB, Gibbon M, Spitzer RL. 1997. Structured Clinical Interview for DSM-IV Axis I (SCID-I), Clinician Version. American Psychiatric Press: Washington DC.
13. Gentile S. 2013. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review. Pharmacotherapy 33: 1087.
14. Glick ID, Correll CU, Altamura AC, et al. 2011. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. J Clin Psychiatry 72: 1616–27.
15. Haijma SV, Van Haren N, Cahn W, Koolschijn PC, Hulshoff Pol HE, Kahn RS. 2013. Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull 39: 1129–38.
16. Janicak PG, Glick ID, Marder SR, et al. 2009. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. J Clin Psychiatry 70: 25–35.
17. Kahn RS, Fleischhacker WW, Boter H, et al., EUFEST study group. 2008. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371: 1085–97.
18. Kane JM. 1996. Schizophrenia. N Engl J Med 334: 34–41.
19. Karthik MS, Kulhara P, Chakrabarti S. 2013. Attitude towards second-generation antipsychotics among patients with schizophrenia and their relatives. Hum Psychopharmacol 28: 457–465.
20. Kennedy J, Tien YY, Cohen LJ, et al. 2009. The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey. Clin Ther 31: 2931–9.
21. King DJ. 1998. Drug treatment of the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 8: 33–42.
22. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. 2013. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry 18: 53–66.
23. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. 2005. What does the PANSS mean? Schizophr Res 79: 231–8.
24. Leucht S, Tardy M, Komossa K, et al. 2012. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 379: 2063–71.
25. Lewis S, Lieberman J. 2008. CATIE and CUtLASS: can we handle the truth? Br J Psychiatry 192: 161–3.
26. McEvoy JP, Byerly M, Hamer RM, et al. 2014. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA 311: 1978–87.
27. McGrath J, Saha S, Chant D, Welham J. 2008. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30: 67–76.
28. Meyer-Lindenberg A, Tost H. 2014. Neuroimaging and plasticity in schizophrenia. Restor Neurol Neurosci 32: 119–27.
29. Nielsen J, Jensen SO, Friis RB, Valentin JB, Correll CU. 2015. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study. Schizophr Bull 41: 627–636.
30. Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. 2012. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treat 2012: 916198.
31. Penttilä M, Jääskeläinen E, Hirvonen N, Isohanni M, Miettunen J. 2014. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 205: 88–94.
32. Peuskens J, Gillain B, De Graeve D, Van Vleymen B, Albert A. 2009. Belgian Schizophrenia Outcome Survey—results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. Eur Psychiatry 24: 154–63.
33. Sampson S, Joshi K, Mansour M, Adams CE. 2013. Intermittent drug techniques for schizophrenia. Schizophr Bull 39: 960–1.
34. Soares-Weiser K, Béchard-Evans L, Lawson AH, Davis J, Ascher-Svanum H. 2013. Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Eur Neuropsychopharmacol 23: 118–25.